JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

Home・Aandelen Lijst・Pulse Biosciences Inc

Pulse Biosciences Inc

Open

SectorGezondheidszorg

20.83 2.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.01

Max

20.83

Belangrijke statistieken
By Trading Economics
Inkomsten	2M -17M
Verkoop	178K 264K
EPS	-0.18
Winstmarge	-6,603.409
Werknemers	116
EBITDA	2M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+37.43% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	582M 1.5B
Vorige openingsprijs	18.57
Vorige sluitingsprijs	20.83

Nieuwssentiment

By Acuity

91%

11 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

16.59 / 17.17 Steun & Weerstand

Pulse Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 apr 2026, 23:53 UTC

Winsten

Naver Posts Weaker First-Quarter Earnings

29 apr 2026, 23:41 UTC

Populaire aandelen

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr 2026, 23:55 UTC

Winsten

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr 2026, 23:54 UTC

Winsten

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr 2026, 23:52 UTC

Winsten

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr 2026, 23:51 UTC

Winsten

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr 2026, 23:51 UTC

Marktinformatie

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr 2026, 23:24 UTC

Winsten

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr 2026, 23:24 UTC

Winsten

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr 2026, 23:24 UTC

Winsten

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr 2026, 23:24 UTC

Winsten

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr 2026, 23:22 UTC

Winsten

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr 2026, 23:22 UTC

Winsten

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr 2026, 23:20 UTC

Winsten

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr 2026, 23:20 UTC

Winsten

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr 2026, 23:19 UTC

Winsten

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr 2026, 23:19 UTC

Winsten

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr 2026, 23:19 UTC

Winsten

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr 2026, 23:19 UTC

Winsten

China Vanke 1Q Loss Narrows>000002.SZ

29 apr 2026, 23:18 UTC

Winsten

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr 2026, 23:17 UTC

Winsten

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr 2026, 23:15 UTC

Winsten

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr 2026, 23:15 UTC

Winsten

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr 2026, 23:13 UTC

Winsten

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr 2026, 23:12 UTC

Winsten

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr 2026, 23:11 UTC

Winsten

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr 2026, 23:11 UTC

Winsten

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr 2026, 23:04 UTC

Winsten

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr 2026, 23:04 UTC

Winsten

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer Vergelijking

Prijswijziging

Pulse Biosciences Inc Prognose

Koersdoel

By TipRanks

37.43% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 30 USD 37.43%

Hoogste 30 USD

Laagste 30 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pulse Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Pulse Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

16.59 / 17.17Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

11 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.